BRPI0819902A2 - C2-c5-alquil-imidazol-bifosfonatos - Google Patents

C2-c5-alquil-imidazol-bifosfonatos

Info

Publication number
BRPI0819902A2
BRPI0819902A2 BRPI0819902-7A BRPI0819902A BRPI0819902A2 BR PI0819902 A2 BRPI0819902 A2 BR PI0819902A2 BR PI0819902 A BRPI0819902 A BR PI0819902A BR PI0819902 A2 BRPI0819902 A2 BR PI0819902A2
Authority
BR
Brazil
Prior art keywords
bisphosphonates
alkyl imidazole
imidazole
alkyl
imidazole bisphosphonates
Prior art date
Application number
BRPI0819902-7A
Other languages
English (en)
Inventor
Sven Weiler
Leo Widler
Jean-Michel Rondeau
Simona Cotesta
Wolfgang Jahnke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39154111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0819902(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0819902A2 publication Critical patent/BRPI0819902A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0819902-7A 2007-11-30 2008-11-26 C2-c5-alquil-imidazol-bifosfonatos BRPI0819902A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07122016 2007-11-30
PCT/EP2008/066245 WO2009068567A1 (en) 2007-11-30 2008-11-26 C2-c5-alkyl-imidazole-bisphosphonates

Publications (1)

Publication Number Publication Date
BRPI0819902A2 true BRPI0819902A2 (pt) 2015-05-19

Family

ID=39154111

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819902-7A BRPI0819902A2 (pt) 2007-11-30 2008-11-26 C2-c5-alquil-imidazol-bifosfonatos

Country Status (24)

Country Link
US (2) US7977323B2 (pt)
EP (1) EP2225252B1 (pt)
JP (1) JP5244917B2 (pt)
KR (1) KR20100092035A (pt)
CN (1) CN101835787A (pt)
AR (1) AR069437A1 (pt)
AU (1) AU2008328797B2 (pt)
BR (1) BRPI0819902A2 (pt)
CA (1) CA2701516A1 (pt)
CL (1) CL2008003545A1 (pt)
CO (1) CO6280421A2 (pt)
CR (1) CR11362A (pt)
EA (1) EA201000860A1 (pt)
EC (1) ECSP10010321A (pt)
ES (1) ES2386851T3 (pt)
IL (1) IL204657A0 (pt)
MA (1) MA31895B1 (pt)
MX (1) MX2010005786A (pt)
NZ (1) NZ584219A (pt)
PE (1) PE20091038A1 (pt)
TN (1) TN2010000138A1 (pt)
TW (1) TW200932248A (pt)
WO (1) WO2009068567A1 (pt)
ZA (1) ZA201001992B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102046152A (zh) * 2008-04-04 2011-05-04 诺瓦提斯公司 含有双膦酸盐的药物组合物
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US8399023B2 (en) 2009-07-31 2013-03-19 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9290526B2 (en) 2010-05-28 2016-03-22 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US8816082B2 (en) 2010-05-28 2014-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
CN102659840B (zh) * 2012-05-10 2013-08-14 苏州普瑞诺药物技术有限公司 咪唑双膦酸类化合物及其可药用盐及药物用途
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
EP3698797A1 (en) 2017-10-16 2020-08-26 Tsinghua University Mevalonic acid pathway inhibitor and pharmaceutical composition thereof
CN112980809B (zh) * 2021-03-17 2023-04-11 云南中烟工业有限责任公司 一种烟草法尼基焦磷酸合酶基因及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84497A (en) 1986-11-21 1994-10-21 Ciba Geigy Ag History 2-) Imidazol-1-yl (ethane-1,1-diphosphonic acid, their preparation and pharmaceutical preparations containing them
ATE119777T1 (de) * 1991-02-26 1995-04-15 Procter & Gamble Pharma Behandlungsmethoden für osteoporose.
GB9324143D0 (en) 1993-11-24 1994-01-12 Schering Agrochemicals Ltd Triazole phosphonate pesticides
GB0029018D0 (en) * 2000-11-28 2001-01-10 Strakan Group Plc Dermatological formulations
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
WO2006039721A2 (en) 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8012949B2 (en) 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
AU2007304205A1 (en) 2006-10-05 2008-04-10 Novartis Ag Pharmaceutical compositions comprising bisphosphonates
CN101679422A (zh) 2007-03-28 2010-03-24 阵列生物制药公司 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物

Also Published As

Publication number Publication date
ECSP10010321A (es) 2010-08-31
EP2225252B1 (en) 2012-06-27
CL2008003545A1 (es) 2009-06-05
WO2009068567A1 (en) 2009-06-04
US7977323B2 (en) 2011-07-12
JP5244917B2 (ja) 2013-07-24
US20110224173A1 (en) 2011-09-15
TN2010000138A1 (en) 2011-09-26
CO6280421A2 (es) 2011-05-20
PE20091038A1 (es) 2009-08-19
EP2225252A1 (en) 2010-09-08
AU2008328797A1 (en) 2009-06-04
MA31895B1 (fr) 2010-12-01
TW200932248A (en) 2009-08-01
CN101835787A (zh) 2010-09-15
ES2386851T3 (es) 2012-09-03
KR20100092035A (ko) 2010-08-19
AR069437A1 (es) 2010-01-20
ZA201001992B (en) 2010-12-29
EA201000860A1 (ru) 2010-12-30
NZ584219A (en) 2012-03-30
CA2701516A1 (en) 2009-06-04
JP2011504908A (ja) 2011-02-17
MX2010005786A (es) 2010-06-09
US20090143337A1 (en) 2009-06-04
CR11362A (es) 2010-06-14
IL204657A0 (en) 2010-11-30
AU2008328797B2 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
BRPI0819902A2 (pt) C2-c5-alquil-imidazol-bifosfonatos
BRPI0922904A2 (pt) "compostos"
BRPI0910229A2 (pt) Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos
DK2196089T3 (da) Fungicidsammensætninger
BRPI1015540A2 (pt) ''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750''
BRPI0914746A2 (pt) composições fungicidas
DK2185567T3 (da) Substituerede bicyclolactam-forbindelser
BRPI0813500A2 (pt) Compostos antivirais
BRPI1007878A2 (pt) "compostos inseticidas"
ATE554776T1 (de) Antivirale phosphinatverbindungen
BRPI0811433A2 (pt) compostos do tipo triazolil aminopirimidina
BRPI0914759A2 (pt) derivado de alquil pirimidin-4-ona substituída
BRPI0814424A2 (pt) Compostos heterociclila
DK2308869T3 (da) Azolforbindelse
BRPI0720097A2 (pt) Compostos de fosfonato
BRPI0914533A2 (pt) "métodos"
BRPI0809996A2 (pt) Compostos
MA30860B1 (fr) Myrtillier denomme "c97-390"
BRPI0924887A2 (pt) Compostos de fenilalquil-imidazol-bifosfonato
FR2936764B1 (fr) Couloir d'intercirculation
ES1068308Y (es) Zapatilla de baño
BRPI0820430A2 (pt) Composto
BRPI0811860A2 (pt) Compostos de (fenil)imidazolil)metilheteroarila
DK2160386T3 (da) Terapeutiske ((phenyl)imidazolyl)methylquinolinylforbindelser
TH94756B (th) สารประกอบฟอสฟิเนทต้านไวรัส

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.